Differentiated ADC product pipeline. DualityBio has a robust pipeline of in-house discovered antibody-drug conjugate (ADC) candidates which is a testament to the Company's prowess in ADC innovation.
What is covered in the Full Insight:
Investment thesis
Differentiated ADC product pipeline
Eye on global markets with a replicable partnership model
Initiate at BUY with TP of HK$270.34
DB-1311/BNT324, a B7-H3 ADC candidate with global market potential
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.